Fig. 1: Metastatic melanoma cells show high sensitivity to lurbinectedin. | Nature Communications

Fig. 1: Metastatic melanoma cells show high sensitivity to lurbinectedin.

From: Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity

Fig. 1

a Chemical structure of lurbinectedin, the first-in-class synthetic ecteinascidin containing tetrahydroisoquinoline subunits. The moiety of the molecule interacting with DNA is indicated. Molecular Weight (MW) is indicated. b Protein lysates from either the immortalized Hermes3A melanocytes, differentiated melanoma cells 501mel, MM011, MM074, MM117, IGR37 and SKMel-28 or undifferentiated melanoma cells MM029, MM047, MM099 and IGR39 were immuno-blotted for proteins as indicated. Molecular mass of the proteins is indicated (kDa). Source data are provided as a Source Data file. This experiment was repeated independently three times with similar results. c–f Indicated melanoma cells were treated with increasing concentrations of vemurafenib c, dabrafenib d, trametinib e, or lurbinectedin f for 72 h. Mean growth is shown relative to vehicle (DMSO)-treated cells. Error bars indicate mean values +/− Standard Deviation (SD) for three biological triplicates. Differentiated (MITF-High, proliferative) melanoma cells are shown in blue, while undifferentiated (MITF-low, invasive) melanoma cells are shown in red. Hyperpigmented melanoma cells with acquired resistance to vemurafenib are shown in green. Immortalized Hermes3A melanocytes, skin keratinocyte HaCaT and embryonic fibroblastic MRC5 cells are shown in violet. Source data are provided as a Source Data file.

Back to article page